A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
Clinical trial NCT02869243 · COMPLETED
Trial details
- NCT number
- NCT02869243
- Sponsor
- Stemgen
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-18
- Primary completion
- 2020-10-16
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.